87377-08-0
87377-08-0
Chemical Structure
Indomethacin-d4
Synonym(s): Indometacin-d4
- CAS No.: 87377-08-0
- Formula:C19H12D4ClNO4
- Molecular Weight:361.81
IUPAC Name: 2-(1-(4-chlorobenzoyl-2,3,5,6-d4-2,3,5,6-d4)-5-methoxy-2-methyl-1H-indol-3-yl)acetic acid
InChIKey: CGIGDMFJXJATDK-LNFUJOGGSA-N
SMILES: O=C(O)CC1=C(C)N(C(C2=C([2H])C([2H])=C(Cl)C([2H])=C2[2H])=O)C3=C1C=C(OC)C=C3
Biological Activity: Indomethacin-d4 (Indometacin-d4) is a deuterium labeled Indomethacin. Indomethacin is a potent, blood-brain permeable and nonselective inhibitor of COX1 and COX2, with IC50s of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHO cells[1]. Indomethacin disrupts autophagic flux by disturbing the normal functioning of lysosomes[2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Indomethacin-d4 | Indomethacin-d4 (Indometacin-d4) is a deuterium labeled Indomethacin. Indomethacin is a potent, blood-brain permeable and nonselective inhibitor of COX1 and COX2, with IC50s of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHO cells. Indomethacin disrupts autophagic flux by disturbing the normal functioning of lysosomes. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Indomethacin (GMP) | Indomethacin (GMP) is Indomethacin (HY-14397) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Indomethacin (Indometacin) is a potent, orally active COX1/2 inhibitor with IC50 values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin has anticancer activity and anti-infective activity. Indomethacin can be used for cancer, inflammation and viral infection research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Indomethacin (Standard) | 99.81% | Indomethacin (Standard) is the analytical standard of Indomethacin. This product is intended for research and analytical applications. Indomethacin (Indometacin) is a potent, orally active COX1/2 inhibitor with IC50 values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin has anticancer activity and anti-infective activity. Indomethacin can be used for cancer, inflammation and viral infection research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Indomethacin-13C6 | Indomethacin-13C6 (Indometacin-13C6) is 13C labeled Indomethacin. Indomethacin (Indometacin) is a potent, orally active COX1/2 inhibitor with IC50 values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin has anticancer activity and anti-infective activity. Indomethacin can be used for cancer, inflammation and viral infection research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Indometacin-d7 | Indometacin-d7 is deuterated labeled Indomethacin (HY-14397). Indomethacin (Indometacin) is a potent, orally active COX1/2 inhibitor with IC50 values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin has anticancer activity and anti-infective activity. Indomethacin can be used for cancer, inflammation and viral infection research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Indomethacin | 99.90% | Indomethacin (Indometacin) is a potent, orally active COX1/2 inhibitor with IC50 values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin has anticancer activity and anti-infective activity. Indomethacin can be used for cancer, inflammation and viral infection research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Riendeau D, et al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol. 1997 May;121(1):105-17. [Content Brief]
- [2]. Jorge Vallecillo-Hernández, et al. Indomethacin Disrupts Autophagic Flux by Inducing Lysosomal Dysfunction in Gastric Cancer Cells and Increases Their Sensitivity to Cytotoxic Drugs. Sci Rep. 2018 Feb 26;8(1):3593. [Content Brief]
